The expression and phosphorylation of ezrin and merlin in human pancreatic cancer

Zhou,Jiahua; Feng,Yongjiang; Tao,Ketao; Su,Zhanhai; Yu,Xiaojin; Zheng,Jie; Zhang,Lihua; Yang,Detong

doi:10.3892/ijo.2014.2381

The expression and phosphorylation of ezrin and merlin in human pancreatic cancer

Authors:
- Jiahua Zhou
- Yongjiang Feng
- Ketao Tao
- Zhanhai Su
- Xiaojin Yu
- Jie Zheng
- Lihua Zhang
- Detong Yang
View Affiliations

Affiliations: Department of General Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, P.R. China, Basic Medical Research Center, Qinghai University, Xining 810001, P.R. China, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, P.R. China, Department of Pathology, School of Medicine, Southeast University, Nanjing 210009, P.R. China, Department of Surgical Pathology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, P.R. China
Published online on: April 10, 2014 https://doi.org/10.3892/ijo.2014.2381
Pages: 2059-2067

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic carcinoma is the most common pancreatic malignancy and is associated with a very poor prognosis. Therefore, new prognostic factors and new treatment strategies are clearly needed. In this study, we retrospectively studied the levels of phosphorylated ezrin in 19 patients with pancreatic carcinoma by immunohistochemical analysis and determined the correlation between protein expression, clinicopathological characteristics and prognosis in pancreatic adenocarcinoma. We also characterized the phenotype of the overexpression of wild-type and phosphorylated ezrin and merlin in human pancreatic cancer cell lines. A significant correlation between the levels of phosphorylated ezrin 353 and ezrin 567 and the stage of pancreatic cancer was observed. Moreover, Kaplan-Meier analysis revealed that patients with high levels of phosphorylated ezrin had a significantly poorer survival rate (P<0.05). In addition, the overexpression of wild-type merlin or ezrin inhibited cell proliferation, migration and adhesion. However, the overexpression of T567D ezrin, a mutant that mimics permanent phosphorylation, promoted the proliferation, adhesion and migration of the pancreatic adenocarcinoma cell line SW1990. The overexpression of S518D merlin inhibited the growth of SW1990 and did not affect migration or adhesion. These results suggest that the phosphorylation of ezrin may contribute to the progression of pancreatic carcinoma and that the level of phosphorylated ezrin may serve as an adverse prognostic factor for pancreatic carcinoma.

View Figures

View References

1.	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Chen WQ, Wang QS, Zhang SW, et al: An analysis of incidence and mortality of pancreas cancer in China 2003–2007. China Cancer. 21:248–253. 2012.
3.	Siegel R, Naishadham D and Jemal A: Cancer Statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
4.	Cartwright T, Richards DA and Boehm KA: Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control. 15:308–313. 2008.PubMed/NCBI
5.	Wan X, Mendoza A, Khanna C and Helman LJ: Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 65:2406–2411. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Diakowski W, Grzybek M and Sikorski AF: Protein 4.1, a component of the erythrocyte membrane skeleton and its related homologue proteins forming the protein 4.1/FERM superfamily. Folia Histochem Cytobiol. 44:231–248. 2006.PubMed/NCBI
7.	Wakayama T, Nakata H, Kurobo M, et al: Expression, localization, and binding activity of the ezrin/radixin/moesin proteins in the mouse testis. J Histochem Cytochem. 57:351–362. 2009. View Article : Google Scholar
8.	Arpin M, Chirivino D, Naba A and Zwaenepoel I: Emerging role for ERM proteins in cell adhesion and migration. Cell Adh Migr. 5:199–206. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Jörgren F, Nilbert M, Rambech E, et al: Ezrin expression in rectal cancer predicts time to development of local recurrence. Int J Colorectal Dis. 27:893–899. 2012.PubMed/NCBI
10.	Arslan AA, Silvera D, Arju R, et al: Atypical ezrin localization as a marker of locally advanced breast cancer. Breast Cancer Res Treat. 134:981–988. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Evans DG, Ramsden RT, Shenton A, et al: What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors? J Neurosurg. 108:92–96. 2008. View Article : Google Scholar
12.	Tsukita S, Yonemura S and Tsukita S: ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci. 22:53–58. 1997. View Article : Google Scholar : PubMed/NCBI
13.	Ye K: Phosphorylation of merlin regulates its stability and tumor suppressive activity. Cell Adh Migr. 1:196–198. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Muranen T, Grönholm M, Lampin A, et al: The tumor suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton. Hum Mol Genet. 16:1742–1751. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Kissil JL, Wilker EW, Johnson KC, et al: Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell. 12:841–849. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Alfthan K, Heiska L, Grönholm M, et al: Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem. 279:18559–18566. 2004. View Article : Google Scholar
17.	Jin H, Sperka T, Herrlich P and Morrison H: Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature. 442:576–579. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Bruce B, Khanna G, Ren L, et al: Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis. 24:69–78. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Hunter KW: Ezrin, a key component in tumor metastasis. Trends Mol Med. 10:201–204. 2004. View Article : Google Scholar
20.	Yu Y, Khan J, Khanna C, et al: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six 1 as keymetastatic regulators. Nat Med. 10:175–181. 2004. View Article : Google Scholar
21.	Ohtani K, Sakamoto H, Rutherford T, et al: Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett. 147:31–38. 1999. View Article : Google Scholar : PubMed/NCBI
22.	Hiscox S and Jiang WG: Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. Cell Sci. 112:3081–3090. 1999.PubMed/NCBI
23.	Ren L, Hong SH, Cassavaugh J, et al: The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene. 28:792–802. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Wittekind C and Oberschmid B: TNM classification of malignant tumors 2010: General aspects and amendments in the general section. Pathologe. 31:333–338. 2010.(In German).
25.	Cui Y, Li T, Zhang D and Han J: Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest. 28:242–247. 2010. View Article : Google Scholar : PubMed/NCBI
26.	Mathew J, Hines JE, Obafunwa JO, et al: CD44 is expressed in hepatocellular carcinomas showing vascular invasion. J Pathol. 179:74–79. 1996. View Article : Google Scholar : PubMed/NCBI
27.	Moilanen J, Lassus H, Leminen A, et al: Ezrin immumoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol. 90:273–281. 2003. View Article : Google Scholar : PubMed/NCBI